Which CT Perfusion Parameter Best Reflects Cerebrovascular Reserve?: Correlation of Acetazolamide-Challenged CT Perfusion with Single-Photon Emission CT in Moyamoya Patients

References

1. ↵
   Endo H, Inoue T, Ogasawara K, et al. Quantitative assessment of cerebral hemodynamics using perfusion-weighted MRI in patients with major cerebral artery occlusive disease: comparison with positron emission tomography. Stroke 2006;37:388–92

   Abstract/FREE Full Text
2. ↵
   Kuroda S, Houkin K, Kamiyama H, et al. Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion: can acetazolamide test predict it? Stroke 2001;32:2110–16

   Abstract/FREE Full Text
3. ↵
   Ogasawara K, Ogawa A, Yoshimoto T. Cerebrovascular reactivity to acetazolamide and outcome in patients with symptomatic internal carotid or middle cerebral artery occlusion: a xenon-133 single-photon emission computed tomography study. Stroke 2002;33:1857–62

   Abstract/FREE Full Text
4. ↵
   Schroeder T. Cerebrovascular reactivity to acetazolamide in carotid artery disease: enhancement of side-to-side CBF asymmetry indicates critically reduced perfusion pressure. Neurol Res 1986;8:231–36

   PubMed
5. ↵
   Yamamoto S, Watanabe M, Uematsu T, et al. Correlation of angiographic circulation time and cerebrovascular reserve by acetazolamide-challenged single photon emission CT. AJNR Am J Neuroradiol 2004;25:242–47

   Abstract/FREE Full Text
6. ↵
   Chen A, Shyr MH, Chen TY, et al. Dynamic CT perfusion imaging with acetazolamide challenge for evaluation of patients with unilateral cerebrovascular steno-occlusive disease. AJNR Am J Neuroradiol 2006;27:1876–81

   Abstract/FREE Full Text
7. ↵
   Eastwood JD, Alexander MJ, Petrella JR, et al. Dynamic CT perfusion imaging with acetazolamide challenge for the preprocedural evaluation of a patient with symptomatic middle cerebral artery occlusive disease. AJNR Am J Neuroradiol 2002;23:285–87

   Abstract/FREE Full Text
8. ↵
   Kaneko K, Kuwabara Y, Mihara F, et al. Validation of the CBF, CBV, and MTT values by perfusion MRI in chronic occlusive cerebrovascular disease: a comparison with 15O-PET. Acad Radiol 2004;11:489–97

   CrossRefPubMed
9. ↵
   Lythgoe DJ, Ostergaard L, William SC, et al. Quantitative perfusion imaging in carotid artery stenosis using dynamic susceptibility contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2000;18:1–11

   CrossRefPubMedWeb of Science
10. ↵
    Suzuki J, Kodama N. Moyamoya disease: a review. Stroke 1983;14:104–10

    Abstract/FREE Full Text
11. ↵
    Wintermark M, Maeder P, Thiran JP, et al. Quantitative assessment of regional cerebral blood flows by perfusion CT studies at low injection rates: a critical review of the underlying theoretical models. Eur Radiol 2001;11:1220–30

    CrossRefPubMedWeb of Science
12. ↵
    Axel L. Tissue mean transit time from dynamic computed tomography by a simple deconvolution technique. Invest Radiol 1983;8:94–99
13. ↵
    Ozgur HT, Kent Walsh T, Masaryk A, et al. Correlation of cerebrovascular reserve as measured by acetazolamide-challenged SPECT with angiographic flow patterns and intra- or extracranial arterial stenosis. AJNR Am J Neuroradiol 2001;22:928–36

    Abstract/FREE Full Text
14. ↵
    Van der Zwan A, Hillen B, Tulleken CAF, et al. Variability of the territories of the major cerebral arteries. J Neurosurg 1992;77:927–40

    PubMedWeb of Science
15. ↵
    Hupperts RMM, Lodder J, Heuts-van Raak, et al. Borderzone brain infarcts on CT taking into account the variability in vascular supply areas. Cerebrovasc Dis 1996;6:294–300

    CrossRef
16. ↵
    Kikuchi K, Murase K, Miki H, et al. Quantitative evaluation of mean transit times obtained with dynamic susceptibility contrast-enhanced MR imaging and with ¹³³Xe SPECT in occlusive cerebrovascular disease. Am J Roentgenol 2002;179:229–35

    PubMed
17. ↵
    Yamauchi H, Okazawa H, Sugimoto K, et al. The effect of deafferentation on cerebral blood flow response to acetazolamide. AJNR Am J Neuroradiol 2004;25:92–96

    Abstract/FREE Full Text
18. ↵
    Nariai T, Suzuki R, Hirakawa K, et al. Vascular reserve in chronic cerebral ischemia measured by the acetazolamide challenge test: comparison with positron-emission tomography. AJNR Am J Neuroradiol 1995;16:563–70

    Abstract
19. ↵
    Yamauchi H, Okazawa H, Kishibe Y, et al. Reduced blood flow response to acetazolamide reflects pre-existing vasodilation and decreased oxygen metabolism in major cerebral arterial occlusive disease. Eur J Nucl Med 2002;29:1349–56

    CrossRef
20. ↵
    Derdeyn CP, Grubb RL Jr, Powers WJ. Cerebral hemodynamic impairment: methods of measurement and association with stroke risk. Neurology 1999;53:251–59

    Abstract/FREE Full Text
21. ↵
    Webster MW, Makaroun MS, Steed DL, et al. Compromised cerebral blood flow reactivity is a predictor of stroke in patients with symptomatic carotid artery occlusive disease. J Vasc Surg 1995;21:338–45

    CrossRefPubMedWeb of Science
22. ↵
    Calamante F, Ganesan V, Kirkham FJ, et al. MR perfusion imaging in Moyamoya syndrome: potential implications for clinical evaluation of occlusive cerebrovascular disease. Stroke 2001;32:2810–16

    Abstract/FREE Full Text
23. ↵
    Togao O, Mihara F, Yoshiura T, et al. Cerebral hemodynamics in Moyamoya disease: correlation between perfusion-weighted MR imaging and cerebral angiography. AJNR Am J Neuroradiol 2006;27:391–97

    Abstract/FREE Full Text
24. ↵
    Calamante F, Mørup M, Hansen LK. Defining a local arterial input function for perfusion MRI using independent component analysis. Magn Reson Med 2004;52:789–97

    CrossRefPubMed